Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420121 | 1.00 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL14154548 | 1.00 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL14551315 | 0.84 | CA2 (0.30) | — | |
| SCHEMBL7152051 | 0.82 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL7153923 | 0.82 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL24686932 | 0.80 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL10051725 | 0.80 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL10183388 | 0.79 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL10183868 | 0.74 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL14154550 | 0.74 | GBA1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673586-B2 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2014-03-18 | — | — | US | disclosed |
| US-20130011852-A1 | COMPOUNDS THAT INTERACT WITH KINASES | ALCHEMIA LIMITED (AU) | 2013-01-10 | — | — | US | disclosed |
| US-20080176815-A1 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2008-07-24 | — | — | US | disclosed |
| US-7291623-B2 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176815-A1 | Compounds that interact with kinases | MAP3K6, MAP3K20, MAP4K2 | PI4KA 272/4885PI4K2B 259/4885PI4K2A 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.